Treprostinil - Generic Drug Details

What are the generic sources for treprostinil and what is the scope of patent protection?

Treprostinil is the generic ingredient in six branded drugs marketed by United Therap, Alembic Global, Dr Reddys, Ph Health, Sandoz, Teva Pharms Usa, and Liquidia Tech, and is included in eleven NDAs. There are twenty-five patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Treprostinil has one hundred and twenty-five patent family members in seventeen countries.

There are nineteen drug master file entries for treprostinil. Five suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for treprostinil

International Patents:	125
US Patents:	25
Tradenames:	6
Applicants:	7
NDAs:	11
Drug Master File Entries:	19
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	64
Clinical Trials:	118
Patent Applications:	2,464
Drug Prices:	Drug price trends for treprostinil
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for treprostinil
What excipients (inactive ingredients) are in treprostinil?	treprostinil excipients list
DailyMed Link:	treprostinil at DailyMed

See drug prices for treprostinil

Recent Clinical Trials for treprostinil

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Liquidia Technologies, Inc.	PHASE3
Pulmovant, Inc.	PHASE2
Shanghai Zhongshan Hospital	PHASE2

See all treprostinil clinical trials

Generic filers with tentative approvals for TREPROSTINIL

Applicant	Application No.	Strength	Dosage Form
		0.4MG/ML	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
		0.2MG/ML	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
		0.1MG/ML	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for treprostinil

Drug Class	Prostacycline Vasodilator
Physiological Effect	Vasodilation

Anatomical Therapeutic Chemical (ATC) Classes for treprostinil

B01AC	Platelet aggregation inhibitors excl. heparin
B01A	ANTITHROMBOTIC AGENTS
B01	ANTITHROMBOTIC AGENTS
B	Blood and blood forming organs

Paragraph IV (Patent) Challenges for TREPROSTINIL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TYVASO	Inhalation Solution	treprostinil	0.6 mg/mL, 2.9 mL ampules	022387	1	2015-04-13
REMODULIN	Injection	treprostinil	1 mg/mL, 2.5 mg/mL, and 5 mg/mL, 20 mL vial	021272	1	2012-12-07
REMODULIN	Injection	treprostinil	10 mg/mL, 20 mL vial	021272	1	2011-12-02

US Patents and Regulatory Information for treprostinil

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005-004	May 23, 2025		RX	Yes	Yes	11,712,442
United Therap	REMODULIN	treprostinil	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021272-008	Sep 28, 2023		RX	Yes	Yes	8,653,137
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-001	May 23, 2022		RX	Yes	Yes	10,421,729		Y
United Therap	REMODULIN	treprostinil	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021272-008	Sep 28, 2023		RX	Yes	Yes	11,723,887			Y
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-001	Dec 20, 2013		RX	Yes	No	8,349,892		Y

Expired US Patents for treprostinil

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
United Therap	REMODULIN	treprostinil	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021272-007	Sep 28, 2023	9,199,908
United Therap	REMODULIN	treprostinil	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021272-002	May 21, 2002	6,765,117
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-003	May 23, 2022	10,130,685
United Therap	REMODULIN	treprostinil	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021272-002	May 21, 2002	10,695,308
United Therap	TYVASO	treprostinil	SOLUTION;INHALATION	022387-001	Jul 30, 2009	5,153,222

EU/EMA Drug Approvals for treprostinil

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
SciPharm Sàrl	Trepulmix	treprostinil	EMEA/H/C/005207Treatment of adult patients with WHO Functional Class (FC) III or IV and:inoperable chronic thromboembolic pulmonary hypertension (CTEPH), orpersistent or recurrent CTEPH after surgical treatmentto improve exercise capacity.	Authorised	no	no	yes	2020-04-03

International Patents for treprostinil

Country	Patent Number	Title	Estimated Expiration
Canada	2654492	ADMINISTRATION DE TREPROSTINIL UTILISANT UN INHALATEUR A DOSE MESUREE (TREPROSTINIL ADMINISTRATION USING A METERED DOSE INHALER)
China	101495122	Treprostinil administration using a metered dose inhaler
European Patent Office	2026816	ADMINISTRATION DE TREPROSTINIL UTILISANT UN INHALATEUR À DOSE MESURÉE (TREPROSTINIL ADMINISTRATION USING A METERED DOSE INHALER)
Spain	2707548
Japan	2009537246

Treprostinil Market Dynamics and Financial Trajectory (US and EU)

Last updated: July 2, 2026

Treprostinil’s near-to-midterm revenue trajectory is driven by (1) adoption of continuous delivery and higher-dose therapy in pulmonary arterial hypertension (PAH) and (2) competitive pressure from inhaled prostacyclins and emerging PAH treatment combinations. In the US, financial performance is materially influenced by uptake of Orenitram (treprostinil extended-release) and Tyvaso (treprostinil inhalation), plus share stability for Remodulin (treprostinil injection) where reimbursement and specialist prescribing anchor persistence. In the EU, demand is more concentrated around injectable and inhaled devices, with slower new uptake where local formularies restrict switching among prostacyclin classes.

Bottom line: treprostinil is in a mature-but-therapeutically sticky segment. Revenues tend to grow when clinician preference shifts from short-acting prostacyclin delivery to sustained exposure and when treatment algorithms expand to higher-risk patients earlier. Revenues can flatten when generic or biosimilar-like substitution is feasible (injectables are typically IP-protected and supply-constrained), and when competing inhaled prostacyclins or oral PAH combinations gain position in high-volume centers.

What drives treprostinil demand in PAH and how does it shift by delivery form?

Demand drivers vary sharply by regimen intensity and route.

PAH treatment algorithms: why treprostinil keeps getting used

Treprostinil is a prostacyclin pathway therapy used across PAH severity tiers. It is most sensitive to clinical practice patterns that prioritize:

• earlier escalation to prostacyclin-class therapy in intermediate/high-risk disease
• combination regimens built around prostacyclin delivery
• titration strategies that maintain hemodynamic targets while limiting side effects

These algorithm shifts affect product mix:

• inhaled treprostinil aligns with patients and centers seeking flexible dosing throughout the day
• oral extended-release aligns with outpatient maintenance when continuous or frequent dosing becomes burdensome
• continuous subcutaneous/intravenous aligns with advanced disease requiring stable drug exposure and rapid titration

Delivery-form mix effect on financial trajectory

Treprostinil’s financial trajectory tracks changing share among these forms:

• Tyvaso tends to benefit from inhaled prostacyclin preference, especially where patients can manage device use and payor coverage supports frequent dosing schedules.
• Orenitram tends to gain when treatment teams and payors support step-down from more burdensome regimens, or when oral maintenance becomes clinically appropriate.
• Remodulin retains revenue where advanced PAH patients require continuous delivery and where switching is difficult due to risk and established clinical response.

How do Tyvaso, Orenitram, and Remodulin revenues typically evolve across the PAH severity curve?

Each product’s trajectory is shaped by different patient segments and clinical switching behaviors.

Tyvaso (treprostinil inhalation)

Key market dynamics

• strong fit in specialty clinics that run inhaled prostacyclin pathways
• device adherence impacts persistence and dose escalation
• payor rules around PAH diagnosis confirmation and step-edit approvals can constrain near-term launches or expansions

What it means financially

• revenue growth generally tracks inhaled prostacyclin penetration and patient persistence
• volatility rises when device-related adoption or payer coverage shifts

Orenitram (treprostinil extended-release)

Key market dynamics

• outpatient convenience drives preference, but tolerability and titration steps can slow conversion
• coverage and formulary positioning govern volume from competing oral and inhaled options
• competition from other PAH oral combinations affects net conversion to oral treprostinil

What it means financially

• growth accelerates when clinicians use Orenitram as a maintenance step after initial stabilization on more intensive regimens

Remodulin (treprostinil injection)

Key market dynamics

• continuous infusion or subcutaneous delivery aligns with advanced disease
• switching risk is high once patients stabilize, which supports persistence
• competitive pressure comes more from prostacyclin class alternatives and from combination strategies rather than direct substitution

What it means financially

• revenue is typically steadier and less sensitive to short-term treatment fashion, but it is still sensitive to patient pool dynamics (incident PAH cases, survival, and escalation rates)

What is the competitive landscape for treprostinil and how does it affect pricing and share?

Treprostinil competes in the prostacyclin and broader PAH therapeutics markets.

Main competitive sets

• other inhaled prostacyclins (lung-delivered routes compete most directly with inhaled treprostinil on convenience and dosing regimen)
• other prostacyclin pathway options (choice depends on route, side-effect profile, and dosing practicality)
• broader PAH oral regimens (endothelin receptor antagonists and PDE5 inhibitors in combination can reduce the addressable population for prostacyclin initiation or delay escalation)

Share-shaping levers

• formulary access and prior authorization design
• patient out-of-pocket costs under commercial coverage
• device usability and training burden for inhaled treprostinil
• ability to titrate to target doses without clinically unacceptable adverse events

Pricing dynamics

In practice, treprostinil revenue often reflects:

• net price discipline from PBM and payer contracting
• utilization changes that can offset price compression
• localized effects where payers restrict step edits to certain prostacyclin brands

How do reimbursement and payer coverage decisions impact treprostinil financial performance?

Treprostinil’s revenue trajectory is sensitive to reimbursement friction typical for PAH:

• prior authorization and evidence requirements for PAH diagnosis
• step therapy policies that require trial of other PAH agents before prostacyclin-class adoption
• documentation burden for dose escalation requests

Commercial vs government mix

• US commercial coverage generally supports higher persistence if payers allow continuation across dose increases.
• Medicaid/Medicare Part D patterns can constrain access depending on state formularies and plan formularies, affecting patient retention and switch rates.

What is the financial trajectory in the US market for treprostinil products?

Trajectory pattern

• growth phases occur when prostacyclin utilization expands in earlier-risk populations and when inhaled or oral routes increase share within prostacyclin therapy.
• plateau phases occur when oral combination regimens delay prostacyclin initiation and when payer coverage becomes more restrictive.

Product-level sensitivity

• Tyvaso is most sensitive to inpatient-to-outpatient transitions and specialty prescribing patterns.
• Orenitram is sensitive to conversion rates and tolerability, plus coverage approvals for long-term maintenance dosing.
• Remodulin is sensitive to incident PAH volumes, escalation rates, and persistence among advanced patients.

When do treprostinil patent and exclusivity milestones drive revenue risk or protection?

Revenue risk is less about immediate generic substitution of treprostinil itself and more about:

• potential late-stage litigation outcomes that could shift market access sooner than planned
• formulation-specific challenges that could erode exclusivity for particular dosage forms
• supply chain changes that can redirect volume temporarily

Practical effect on financial trajectory

• where patent estates are thick for each dosage form, the commercial horizon is typically longer and revenue declines are slower.
• where formulation or delivery-system patents are thinner, the risk is concentrated around specific products like extended-release or inhalation devices.

What patent estate strength issues matter most for treprostinil commercialization?

Key estate questions for treprostinil typically focus on:

• method-of-use claims tied to PAH treatment and dosing/titration paradigms
• formulation claims that protect extended-release behavior and inhalation particle/delivery characteristics
• manufacturing/process claims that limit “work-around” generic development

For business planning, market exposure tends to be product-form specific: generic entry risk for one dosage form does not automatically translate to the others.

Which generics or biosimilar-like risks exist for treprostinil and where is entry most likely?

Treprostinil is a small-molecule prostacyclin analog. Generic risk is typically concentrated where:

• there is a clear path to bioequivalence with an easier-to-replicate formulation
• Orange Book listings for that specific product leave multiple vulnerable patents
• Paragraph IV-type challenges become cost-effective relative to the expected protected sales period

For each dosage form, entry likelihood depends on:

• strength and breadth of listed patents
• ability to replicate formulation and performance characteristics
• litigation timelines and settlement terms that can delay entry

How do Paragraph IV challenges and settlements typically affect treprostinil revenue timing?

The impact on revenue timing is usually expressed through:

• entry delays due to automatic stays after a successful filing
• “launch-blocking” settlements that keep generics off the market until a defined trigger date
• partial risk if some patents are ruled invalid while others remain enforceable

For financial trajectory modeling, the key inputs are:

• earliest possible generic entry date based on patent expirations and litigation stays
• probability of settlement vs adverse court rulings
• how payers respond if competing offerings appear (formulary switching can take quarters)

What is the FDA regulatory status landscape for treprostinil that affects market access?

Treprostinil products are FDA-approved for PAH indications and maintained through:

• labeling updates tied to dosing and patient selection
• REMS or risk management controls where required for specific formulations/devices
• postmarketing requirements impacting lifecycle extensions

Financial trajectory is influenced by whether FDA label expansion improves usable patient populations or if safety changes restrict initiation/titration.

How does treprostinil compare with rival PAH therapies on market uptake and financial durability?

A practical comparison for market dynamics:

• treprostinil’s route-specific convenience supports durable adherence when patients and clinicians prefer prostacyclin delivery continuity.
• oral combinations compete by delaying prostacyclin initiation; this reduces the incremental patient pool that starts on treprostinil.
• the main substitution threat is within the prostacyclin class (inhaled vs oral vs injected decisions), not across all PAH therapy classes.

EU and geographic dynamics: what changes outside the US market?

Outside the US, treprostinil uptake often varies due to:

• reimbursement differences and national health system formulary rules
• hospital-based initiation practices and national PAH center guidelines
• availability of device training programs for inhaled treprostinil

Commercial outcomes in the EU tend to be steadier and slower-moving, with volume changes driven by formulary decisions and center adoption rather than rapid payer preference shifts.

Key revenue exposure map: where treprostinil sits in the value chain

• Patient pool sensitivity: incident PAH volumes, survival, and escalation rates
• Route adoption: inhaled and oral share gains versus injected persistence
• Payer friction: prior authorization, step edits, and coverage continuity during dose escalation
• Lifecycle control: patent and regulatory exclusivity, plus device/formulation defensibility
• Switching behavior: persistence once stable versus clinician willingness to cross over between prostacyclin routes

Key Takeaways

• Treprostinil’s financial trajectory is driven by prostacyclin pathway adoption patterns and by shifts between inhaled, oral extended-release, and continuous injection delivery.
• Revenue durability is supported by persistence in advanced PAH and by route-specific clinical fit, with volatility mainly from payer coverage friction and competition within PAH prostacyclin therapy.
• The most material revenue risk is product-form specific patent and formulation exclusivity rather than broad substitution across all treprostinil presentations.
• US and EU outcomes diverge based on reimbursement controls, center prescribing practices, and device-adoption logistics.

FAQs

1. What patient populations are most likely to initiate treprostinil in PAH under current treatment paradigms?
2. How do prior authorization and step edits influence treprostinil persistence and dose escalation revenue?
3. Which treprostinil product is most sensitive to competitive inhaled prostacyclin switching?
4. How do patent expirations by dosage form typically translate into generic entry risk timing for treprostinil?
5. How does device training and adherence affect inhaled treprostinil commercial outcomes?

References (APA)

1. FDA. (n.d.). Drug Approval and Database Search (Drugs@FDA). https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. (n.d.). Drugs@FDA: Orange Book Data (Approved Drug Products with Therapeutic Equivalence Evaluations). https://www.accessdata.fda.gov/scripts/cder/ob/
3. EMA. (n.d.). EU medicines information for authorized products and EPAR documents. https://www.ema.europa.eu/en/medicines